Cardiol Therapeutics has commenced its pivotal phase II/III clinical trial, MAVERIC-2, focusing on patients with recurrent pericarditis who have discontinued interleukin-1 (IL-1) blocker therapies. This initiative addresses the significant unmet need in managing recurrent pericarditis, a condition often marked by high recurrence rates following cessation of IL-1 blocker treatments.
MAVERIC-2 Trial Details
The MAVERIC-2 trial is designed to evaluate the efficacy and safety of CardiolRx, Cardiol Therapeutics' lead drug candidate, as a potential alternative treatment for recurrent pericarditis. The trial targets patients who have previously used and discontinued IL-1 blocker therapies, which are associated with recurrence rates as high as 75%. Cardiol Therapeutics aims to demonstrate that CardiolRx can offer a more effective and cost-efficient therapeutic option.
Strategic Parallel Trial: MAVERIC-3
In conjunction with MAVERIC-2, Cardiol Therapeutics is planning the MAVERIC-3 trial. The company anticipates that running these trials in parallel could accelerate the regulatory approval process and expand the market reach to include both second- and third-line therapies for recurrent pericarditis.
Financial Backing and Upcoming Data Presentation
To support the MAVERIC-2 trial and ongoing operations, Cardiol Therapeutics recently secured USD 15.5 million through a capital increase. A key upcoming event for the company is the presentation of complete clinical data from its MAVERIC-Pilot phase II study at the American Heart Association Scientific Sessions on November 18, 2024. This presentation is expected to provide further insights into the potential of CardiolRx in treating pericarditis.
